| Flibanserin(BIMT17) |
| 1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one |
| (CAS 167933-07-5) |
 |
| Description： |
Flibanserin (code name BIMT-17; proposed trade name Girosa) is a drug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD).[1][2] Development by Boehringer Ingelheim was halted in October 2010 following a negative report by the U.S. Food and Drug Administration.[3] The rights to the drug were then transferred to Sprout Pharmaceuticals which is continuing the drug development process. |
| Product No. |
KT00361 |
| Product Name |
Flibanserin(BIMT17) |
| Synonyms |
|
| Formal Name |
1-(2-{4-[3-(Trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one |
| CAS Number |
167933-07-5 |
| Molecular Formula |
C20H21F3N4O |
| Formula Weight |
390.4 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
CB 300919
CB30865
GNE-617
GNE-617 hydrochloride
CAY10618
P7C3
Tat-Beclin 1 PeptideSIRT1 (human recombinant) |
|
